Stretch marks are common, not just among pregnant women. Up to 90% of pregnant women, 70% of adolescent females, and 40% of adolescent males have them.1 Although they are not detrimental to health, they can cause other physical symptoms, such as pain, tenderness and itchiness.2 While stretch marks are permanent, there are ways to improve their appearance and make them less noticeable, or even prevent them in the first place.

Despite the heavy use of cosmetic products for stretch marks, like creams and lotions, there have been little clinical evidence to support their effectiveness. This, however, isn’t the case for Stratamark, a silicone gel medical grade device which is the only topical product for the prevention and treatment of stretch marks with proven clinical evidence.

 

Triple mechanism of action

With this complex triple action, Stratamark softens and flattens raised and depressed stretch marks, reduces redness and discoloration, as well as relieves itching and discomfort.

 

Clinically proven Class A medical device

Stratamark is a novel topical medical device specifically designed for the prevention and treatment of stretch marks. Over 500 pregnant women have participated in clinical studies with Stratamark.5,6 Stratamark has been clinically proven to not only help with severity of stretch marks, but also symptoms associated with stretch marks. Stratamark does not contain alcohol, fragrances or parabens, and does not penetrate below the level of the stratum corneum. It is suitable for pregnant women, breastfeeding mothers, children and people with sensitive skin.5,6

 

First clinical study5

Prevention Arm: 148 pregnant women with no existing stretch marks at the abdomen area

·        Stratamark group vs Control group

o   82% vs 39% did not develop stretch marks (p < 0.001)

Treatment Arm: 155 pregnant women with existing stretch marks at the abdomen area

·        Pre-treatment vs Post-treatment

o   80% reported an improvement in the severity of their stretch marks (p < 0.001)

o   88% reported an improvement in the colour of their stretch marks

o   86% reported an improvement in the visibility of their stretch marks

o   83% reported an improvement in the itchiness of their stretch marks

Both Arms:

·        89% rated the tolerability of Stratamark to be “Very Good – Excellent”

·        84% rated the feeling of Stratamark on the skin to be “Very Good – Excellent”

·        81% rated the ease of using Stratamark to be “Very Good – Excellent”

Second clinical study6

Prevention Arm: 139 pregnant women with no existing stretch marks

·        Stratamark group (at 36 to 40 weeks) vs Control group

o   80% vs 39% did not develop stretch marks (p < 0.05)

·        Stratamark group (at 6 to 8 weeks post-partum) vs Control group

o   68% vs 39% did not develop stretch marks (p < 0.05)

Treatment Arm: 133 post-partum women with existing stretch marks

·        Pre-treatment vs Post-treatment

o   Severity of stretch marks improved by 23.5%

o   Colour of stretch marks improved by 54.5%

o   Itchiness of stretch marks improved by 95.6%

 

Although many women use creams and lotions to try to prevent and treat stretch marks, up to 90% of women develop stretch marks during pregnancy.1 Regardless of it being such a common issue, nothing has been clinically proven to effectively prevent and treat them… until Stratamark. Recommend Stratamark to your patients now with confidence!

 

Full prescribing information will be available on request.

 

DCH Auriga (Singapore) Pte. Ltd.

10 Raeburn Park, Block C, #01-33, Singapore 088702

Tel: (65) 6566 1188

Email: enquirysgp@dchauriga.com

 

PMA code (DCHA-MMYY-ZZZ)

 

References

  1. Karia, et al. Journal of Cutaneous and Aesthetic Surgery. 2016;9(2):101-105.
  2. Osman H, et al. Royal College of Obstetricians and Gynaecologists (Great Britain). 2008;115(9):1138-42.
  3. Mustoe T. A. Aesthetic Plastic Surgery. 2008;32(1):82-92.
  4. Quinn, et al. Burns Including Thermal Injury. 1985;12(2):102-108.
  5. Malkova, S. New EU Magazine of Medicine. 2014;1-4/4:1-7.
  6. Hughes CDG, et al. Australasian Journal of Dermatology. 2019;60(1):78-80.

 

All images: Stratamark Singapore